drugset / Trial / NCT06562790

Study of Gamma PN3 in the Elderly

NCT06562790

Phase 1 Completed 105 enrolled GPN Vaccines
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Phase 1 double- blind randomised active comparator dose escalating study of Gamma PN3 in the elderly

Timeline

Start
2024-08-26
Primary completion
2025-03-31
Completion
2025-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Gamma-PN3 Vaccine 500 ug Intramuscular
Subject Gamma-PN3 Vaccine 1000 ug Intramuscular
Subject Gamma-PN3 Vaccine 1500 ug Intramuscular
Comparator Prevnar 13 Vaccine